Director/PDMR Shareholding

RNS Number : 1654L
GlaxoSmithKline PLC
14 July 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

13

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

52

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

17

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

7

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

12

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

60

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

60

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

33

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

36

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017, on shares held through the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.2549

42

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2017-07-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEZLFFDDFBBBB

Companies

GSK (GSK)
UK 100

Latest directors dealings